From the Food and Drug Administration.
Nightingale
S L
SL
Office of Health Affairs, FDA, Rockville, MD 20857.
D000386:AIDS-Related Complex / Q000188:drug therapy*; D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy*; D002985:Clinical Protocols; D016049:Didanosine / Q000627:therapeutic use*; D004341:Drug Evaluation; D006801:Humans; D010300:Parkinson Disease / Q000188:drug therapy*; D010627:Phenethylamines / Q000627:therapeutic use*; D012642:Selegiline / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration
D010627:Phenethylamines; D012642:Selegiline; D016049:Didanosine